drugset / Trial / NCT01201122

Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis

NCT01201122

Phase 4 Completed 86 enrolled Wolfson Medical Center
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate effectiveness of once daily dosing of Pentasa compared with twice daily in children with mild to moderate active ulcerative colitis.

Timeline

Start
2010-09
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 75 mg/kg
Subject Mesalamine Small molecule 500 mg
Subject Mesalamine Small molecule 1000 mg
Subject Mesalamine Small molecule 1500 mg
Subject Mesalamine Small molecule 2000 mg
Subject Mesalamine Small molecule 3000 mg

Indications